AstraZeneca immunotherapy study shows benefit for niche group of lung cancer patients
AstraZeneca attempts a recovery from a July failure with positive results from a new study, also in lung cancer, but aimed at a niche group of patients.
The jackpot cancer immunotherapy ambitions of AstraZeneca stumbled in July with the failure of a closely watched clinical trial in newly diagnosed lung cancer. Friday, the Anglo-Swedish drugmaker attempts a recovery with positive results from a new study, also in lung cancer, but aimed at a niche group of patients.
AstraZeneca still trails cancer immunotherapy leaders Merck and
